Capricorn Energy CNE
NewMed's all-share bid for Capricorn hands shareholders a 42% discount and a self-serving board deal; a cash-return plus Egypt-focused optimisation path unlocks 400p/share instead.
Thesis
Capricorn Energy's board has agreed a second value-destructive deal — an all-share merger with Israel's NewMed Energy — that values Capricorn at a 42% discount to independent ERCE fair value of 315p/share, giving away over US$200m and gifting NewMed a premium LSE listing for free. The transaction is laced with governance red flags: a US$30m management payout, 40% board representation despite only 10% economic ownership, and a coercive US$620m special dividend conditioned on deal approval. Under current management, Capricorn has squandered ~US$3.3bn on failed exploration and run bloated G&A while underperforming E&P peers by 173% over CEO tenure. Palliser's Value Optimisation Plan — immediate cash returns, CVR monetisation, G&A right-sizing, and Egyptian PSC modernisation — unlocks 400p/share, a 61% premium to NewMed's implied value.
SCQA
Capricorn Energy is a UK-listed E&P whose portfolio today is substantially cash, near-term UK and Senegal contingent receivables, and a 50% non-operated interest in Egypt's Western Desert assets acquired from Shell in 2021.
After the Tullow merger collapsed, the board agreed a NewMed all-share deal at a 42% discount to fair value with a US$30m management payout, 40% board seats for 10% ownership, and a US$620m special dividend coercively conditioned on approval.
Reject the NewMed terms, pursue Palliser's Value Optimisation Plan: immediately return the US$620m excess cash, monetise contingent receivables, cut G&A and non-Egypt exploration, and modernise Egyptian PSC terms.
ERCE-independently-validated near-term fair value of 315p/share (29% upside to market, 27% to NewMed implied) plus a further 85p medium-term, reaching 400p — a 63% upside to the current share price.
The three reasons
- 1
NewMed offer values Capricorn at a 42% discount to ERCE's independent £315p/share fair value
- 2
Deal is self-serving: ~US$30m management payout and 40% board seats for only 10% of combined equity
- 3
Palliser's Value Optimisation Plan delivers 400p/share (61% upside to NewMed terms)
Primary demands
- Reject the proposed NewMed Energy all-share merger on current terms
- Immediately distribute US$620 million of excess cash to shareholders as a special dividend unconditional on the NewMed deal
- Monetise or in-specie distribute UK and Senegal contingent value rights (>US$300m)
- Right-size corporate G&A and immediately halt non-committed exploration spend outside Egypt
- Engage Egyptian authorities to modernise PSC terms on Western Desert assets
- Pursue a formal strategic review / sales process if no superior deal materialises in a defined time-frame
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- APA Corporation Egypt PSC modernisation (50% increase in Egyptian FCF capacity)
- Eni Egypt PSC renegotiation (>50% NPV10 uplift)
- TransGlobe Energy Egypt PSC modernisation (>100% netback improvement)
- Failed Tullow Oil merger attempt by Capricorn (prior value-destructive deal)
Notable slides (6)
Notes
Classic UK-listed activist deck from Palliser Capital opposing the Capricorn/NewMed Energy all-share merger announced September 2022. Anchors argument around a third-party ERCE independent valuation report commissioned by Palliser — unusual rhetorical device that lends analytical credibility. Strong SCQA craft: clean section dividers, two full-bleed pull-quote slides (pages 16, 23) that break rhythm and hammer governance critique. Sum-of-parts waterfall on p.8-9 is the centerpiece chart, with color-coded near-term vs medium-term value bridges. Peer-gap TSR table on p.18 is compact and devastating. The world map on p.19 showing failed exploration across 18 countries is a standout rhetorical slide. Stake size not disclosed in this document. Campaign phase is initial_thesis — first public presentation of Palliser's views on this specific transaction, though Palliser notes prior private engagement with the board.